Exacerbation of anthracycline-induced early chronic cardiomyopathy with ATRA: Role of B-Type natriuretic peptide as an indicator of cardiac dysfunction

Kris Michael Mahadeo, Girish Dhall, Lawrence J. Ettinger, Cheryl C. Kurer

Research output: Contribution to journalArticle

4 Scopus citations


Cardiac disease is a significant complication of childhood oncologic therapy. We report the case of a 14-year-old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (ATRA). Despite cessation of daunomycin, she demonstrated fluctuating systolic function in relation to ATRA administration. Improvement and deterioration in systolic function on echocardiogram and serum B-natriuretic peptide levels were seen while receiving ATRA 1 week on and 1 week off, respectively, during the maintenance phase of therapy.

Original languageEnglish (US)
Pages (from-to)134-136
Number of pages3
JournalJournal of Pediatric Hematology/Oncology
Issue number2
Publication statusPublished - Mar 1 2010



  • Acute promyelocytic leukemia
  • All-trans retinoic acid
  • Anthracycline
  • B-natriuretic peptide
  • Cardiotoxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this